Cargando…

Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac

The objective of the present investigation was to study the effect of β-cyclodextrin (β-CD) on the in vitro dissolution of aceclofenac (AF) from molecular inclusion complexes. Aceclofenac molecular inclusion complexes in 1:1 and 1:2 M ratio were prepared using a kneading method. The in vitro dissolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dua, Kamal, Pabreja, Kavita, Ramana, M. V., Lather, Vinny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications Pvt Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178950/
https://www.ncbi.nlm.nih.gov/pubmed/21966164
http://dx.doi.org/10.4103/0975-7406.84457
_version_ 1782212465273077760
author Dua, Kamal
Pabreja, Kavita
Ramana, M. V.
Lather, Vinny
author_facet Dua, Kamal
Pabreja, Kavita
Ramana, M. V.
Lather, Vinny
author_sort Dua, Kamal
collection PubMed
description The objective of the present investigation was to study the effect of β-cyclodextrin (β-CD) on the in vitro dissolution of aceclofenac (AF) from molecular inclusion complexes. Aceclofenac molecular inclusion complexes in 1:1 and 1:2 M ratio were prepared using a kneading method. The in vitro dissolution of pure drug, physical mixtures, and cyclodextrin inclusion complexes was carried out. Molecular inclusion complexes of AF with β-CD showed a considerable increase in the dissolution rate in comparison with the physical mixture and pure drug in 0.1 N HCl, pH 1.2, and phosphate buffer, pH 7.4. Inclusion complexes with a 1:2 M ratio showed the maximum dissolution rate in comparison to other ratios. Fourier transform infrared spectroscopy and differential scanning calorimetry studies indicated no interaction between AF and β-CD in complexes in solid state. Molecular modeling results indicated the relative energetic stability of the β-CD dimer-AF complex as compared to β-CD monomer-AF. Dissolution enhancement was attributed to the formation of water soluble inclusion complexes with β-CD. The in vitro release from all the formulations was best described by first-order kinetics (R(2) = 0.9826 and 0.9938 in 0.1 N HCl and phosphate buffer, respectively) followed by the Higuchi release model (R(2) = 0.9542 and 0.9686 in 0.1 N HCl and phosphate buffer, respectively). In conclusion, the dissolution of AF can be enhanced by the use of a hydrophilic carrier like β-CD.
format Online
Article
Text
id pubmed-3178950
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-31789502011-10-02 Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac Dua, Kamal Pabreja, Kavita Ramana, M. V. Lather, Vinny J Pharm Bioallied Sci Original Article The objective of the present investigation was to study the effect of β-cyclodextrin (β-CD) on the in vitro dissolution of aceclofenac (AF) from molecular inclusion complexes. Aceclofenac molecular inclusion complexes in 1:1 and 1:2 M ratio were prepared using a kneading method. The in vitro dissolution of pure drug, physical mixtures, and cyclodextrin inclusion complexes was carried out. Molecular inclusion complexes of AF with β-CD showed a considerable increase in the dissolution rate in comparison with the physical mixture and pure drug in 0.1 N HCl, pH 1.2, and phosphate buffer, pH 7.4. Inclusion complexes with a 1:2 M ratio showed the maximum dissolution rate in comparison to other ratios. Fourier transform infrared spectroscopy and differential scanning calorimetry studies indicated no interaction between AF and β-CD in complexes in solid state. Molecular modeling results indicated the relative energetic stability of the β-CD dimer-AF complex as compared to β-CD monomer-AF. Dissolution enhancement was attributed to the formation of water soluble inclusion complexes with β-CD. The in vitro release from all the formulations was best described by first-order kinetics (R(2) = 0.9826 and 0.9938 in 0.1 N HCl and phosphate buffer, respectively) followed by the Higuchi release model (R(2) = 0.9542 and 0.9686 in 0.1 N HCl and phosphate buffer, respectively). In conclusion, the dissolution of AF can be enhanced by the use of a hydrophilic carrier like β-CD. Medknow Publications Pvt Ltd 2011 /pmc/articles/PMC3178950/ /pubmed/21966164 http://dx.doi.org/10.4103/0975-7406.84457 Text en Copyright: © Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Dua, Kamal
Pabreja, Kavita
Ramana, M. V.
Lather, Vinny
Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
title Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
title_full Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
title_fullStr Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
title_full_unstemmed Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
title_short Dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
title_sort dissolution behavior of β-cyclodextrin molecular inclusion complexes of aceclofenac
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178950/
https://www.ncbi.nlm.nih.gov/pubmed/21966164
http://dx.doi.org/10.4103/0975-7406.84457
work_keys_str_mv AT duakamal dissolutionbehaviorofbcyclodextrinmolecularinclusioncomplexesofaceclofenac
AT pabrejakavita dissolutionbehaviorofbcyclodextrinmolecularinclusioncomplexesofaceclofenac
AT ramanamv dissolutionbehaviorofbcyclodextrinmolecularinclusioncomplexesofaceclofenac
AT lathervinny dissolutionbehaviorofbcyclodextrinmolecularinclusioncomplexesofaceclofenac